Kapil Dhingra

Investment Partner

Overview

Gender
male
Investor Type
Investment Partner

Kapil Dhingra has served as a member of our board of directors since December 2015. Dr. Dhingra currently serves as the Managing Member of KAPital Consulting, LLC, a healthcare consulting firm that he founded in 2008.

Kapil has over 25 years of experience in oncology clinical research and drug development. From 1999 to 2008, Kapil worked at Hoffmann-La Roche, where he served in roles of increasing responsibility, most recently as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development.

From 2000 to 2008, he held a Clinical Affiliate appointment at Memorial Sloan Kettering Cancer Center. From 1996 to 1999, Kapil worked at Eli Lilly and Company where he served in roles of increasing responsibility, most recently as Senior Clinical Research Physician. Kapil also served as a Clinical Associate Professor of Medicine at the Indiana University School of Medicine from 1997 to 1999.

Prior to Eli Lilly, Kapil was a member of the faculty of M.D. Anderson Cancer Center from 1989 to 1996. Kapil currently serves on the board of directors of Advanced Accelerator Applications S.A., a public pharmaceutical company.

Kapil previously served as a member of the board of directors of Micromet, Inc., until its acquisition by Amgen Inc., and YM Biosciences Inc., until its acquisition by Gilead Sciences, Inc., each of which was a public company during Kapil’s service as a director.

Kapil received his M.B.B.S. degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine.

Jobs

Number of Current Jobs
1
Kapil Dhingra has 1 current jobs including Board Member at Replimune Group , .
Organization Name Title At Company Start Date End Date
Replimune Group Board Member Jul 1, 2017 Detail